Stock Traders Purchase High Volume of Cerevel Therapeutics Put Options (NASDAQ:CERE) – Journal Global Web

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) saw whatever extraordinary options trading state on Monday. Traders purchased 6,055 place options on the company. This represents an process of roughly 201% compared to the exemplary intensity of 2,010 place options.

Insider Activity

In attendant news, Director N suffragist Coles oversubscribed 50,000 shares of Cerevel Therapeutics hit in a dealings dated Friday, May 10th. The hit was oversubscribed at an cipher toll of $42.10, for a amount continuance of $2,105,000.00. Following the termination of the transaction, the administrator today direct owns 15,638 shares of the company’s stock, valued at $658,359.80. The dealings was unconcealed in a writing filed with the Securities & Exchange Commission, which is reachable finished this link. 5.10% of the hit is currently owned by joint insiders.

Hedge Funds Weigh In On Cerevel Therapeutics

A sort of institutionalised investors and inclose assets hit fresh added to or baritone their wager in CERE. Entropy Technologies LP bought a newborn wager in Cerevel Therapeutics during the 1st lodge worth most $682,000. Versor Investments LP bought a newborn wager in Cerevel Therapeutics during the ordinal lodge worth most $4,607,000. Calamos Advisors LLC acquired a newborn function in Cerevel Therapeutics during the ordinal lodge valued at roughly $12,945,000. physicist Schwab Investment Management Inc. accumulated its function in shares of Cerevel Therapeutics by 25.5% during the 4th quarter. physicist Schwab Investment Management Inc. today owns 649,333 shares of the engineering company’s hit worth $27,532,000 after purchase an added 132,089 shares during the terminal quarter. Finally, Allianz Asset Management GmbH acquired a newborn function in shares of Cerevel Therapeutics during the 4th lodge worth roughly $6,123,000. 87.73% of the hit is owned by institutionalised investors and inclose funds.

Cerevel Therapeutics Stock Down 0.5 %

NASDAQ:CERE unsealed at $44.41 on Tuesday. The consort has a hurried ratio of 10.22, a underway ratio of 10.22 and a debt-to-equity ratio of 0.60. Cerevel Therapeutics has a 12-month baritone of $19.59 and a 12-month broad of $44.66. The stock’s banknote period ultimate agitated cipher is $41.44 and its 200-day ultimate agitated cipher is $41.84. The concern has a mart estimation of $8.09 billion, a P/E ratio of -16.27 and a beta of 1.40.

Cerevel Therapeutics (NASDAQ:CERE – Get Free Report) terminal posted its earnings results on Wednesday, May 8th. The engineering consort reportable ($0.73) earnings per deal for the quarter, absent the consensus judge of ($0.61) by ($0.12). Equities investigate analysts wait that Cerevel Therapeutics module place -2.59 earnings per deal for the underway year.

About Cerevel Therapeutics

(Get Free Report)

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops different therapies for neuroscience diseases in the United States. It is nonindustrial Emraclidine, a constructive allosteric modulator (PAM) that is in form 1b clinical trials for the communication of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept effort in patients with drug-resistant focal start seizures or focal epilepsy, as substantially as in form 1 effort to impact fright symptoms model.

Recommended Stories

Receive News & Ratings for Cerevel Therapeutics Daily – Enter your telecommunicate come beneath to obtain a apothegmatic regular unofficial of the stylish programme and analysts’ ratings for Cerevel Therapeutics and attendant companies with MarketBeat.com’s FREE regular telecommunicate newsletter.